Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine

Phase 3 Completed 124 enrolled UCB Pharma

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase 3b, open-label, multicenter trial to assess the safety and tolerability of switching from ropinirole therapy to the rotigotine transdermal system and its effect on symptoms in subjects with idiopathic Parkinson's disease

Timeline

Start: 2007-07
Primary completion: 2007-12
Completion: 2007-12

Publications

Results Kim HJ, Jeon BS, Lee WY, Lee MC, Kim JW, Kim JM, Ahn TB, Cho J, Chung SJ, Grieger F, Whitesides J, Boroojerdi B. Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease. BMC Neurol. 2011 Aug 10;11:100. doi: 10.1186/1471-2377-11-100.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rotigotine	Unknown	2 mg	Other
Subject	Rotigotine	Unknown	4 mg	Other
Subject	Rotigotine	Unknown	6 mg	Other
Subject	Rotigotine	Unknown	8 mg	Other

Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine

Summary

Timeline

Publications

Drugs

Indications